| Bioactivity | Selonsertib (GS-4997), an orally bioavailable, selective apoptosis signal-regulating kinase 1 (ASK1) inhibitor with a pIC50 of 8.3, has been evaluated as an experimental treatment for diabetic nephropathy and kidney fibrosis. | ||||||||||||
| Invitro | Selonsertib (GS-4997) is a clinical stage ASK1 inhibitor, which has been evaluated as an experimental treatment for diabetic nephropathy and kidney fibrosis[1]. Selonsertib (GS-4997) is a highly selective and potent once-daily oral ASK1 inhibitor that competes with ATP in the ASK1 catalytic kinase domain[2]. | ||||||||||||
| Name | Selonsertib | ||||||||||||
| CAS | 1448428-04-3 | ||||||||||||
| Formula | C24H24FN7O | ||||||||||||
| Molar Mass | 445.49 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Selonsertib
CAS: 1448428-04-3 F: C24H24FN7O W: 445.49
Selonsertib (GS-4997), an orally bioavailable, selective apoptosis signal-regulating kinase 1 (ASK1) inhibitor with a pI
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.